Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

Haematologica

Volumn 99, Issue 6, 2014, Pages

  Wolleschak, Denise ^a   Mack, Thomas S ^a   Perner, Florian ^a   Frey, Stephanie ^a   Schnöder, Tina M ^a   Wagner, Marie Christine ^a   Höding, Christine ^a   Pils, Marina C ^b   Parkner, Andreas ^a   Kliche, Stefanie ^a   Schraven, Burkhart ^a,b   Hebel, Katrin ^a   Brunner Weinzierl, Monika ^a   Ranjan, Satish ^a   Isermann, Berend ^a   Lipka, Daniel B ^a,c   Fischer, Thomas ^a   Heidel, Florian H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

AC220; FLT3 ITD; PKC412; T cell activation; Tyrosine kinase inhibitors

Indexed keywords

CD69 ANTIGEN; DASATINIB; IMATINIB; MIDOSTAURIN; NILOTINIB; QUIZARTINIB; T LYMPHOCYTE RECEPTOR; 4'-N-BENZOYLSTAUROSPORINE; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; STAUROSPORINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; CELL PROLIFERATION; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; LETTER; LYMPHOCYTE FUNCTION; MUTATION; NONHUMAN; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

BENZOTHIAZOLES; FMS-LIKE TYROSINE KINASE 3; HUMANS; PHENYLUREA COMPOUNDS; STAUROSPORINE; T-LYMPHOCYTES;

EID: 84901698239     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104331     Document Type: Letter

References (15)

1. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-84.
2. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006;107(1):293-300.
3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-3.
4. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735-41.
5. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia. 2005;19(11):1863-71.
6. Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2007;109(7):2985-8.
7. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6):2473-9.
8. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23(30):7583-93.
9. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254-62.
10. Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12(5B):2107-18.
11. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol. 2008; 36(10):1297-308.
12. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92.
13. Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1, 3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Med Chem. 2009;52(23):7808-16.
14. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007; 7(5):345-56.
15. Wolfl M, Schwinn S, Yoo YE, Ress ML, Braun M, Chopra M, et al. Src-kinase inhibitors sensitize human cells of myeloid origin to Tolllike-receptor-induced interleukin 12 synthesis. Blood. 2013; 122(7):1203-13.